AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01115790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: Prexasertib IV on day 1 of a 14 day cycle. The expected duration is 3 cycles (2 weeks each for a total of 6 weeks). Participants receiving clinical benefit may remain on study until disease progression, unacceptable toxicity or other criteria for discontinuation are met.
Study NCT01492530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Men of African American Legacy Empowering Self
Description: Small group intervention. 6 main sessions + 2 booster sessions. Each session lasts 2 hours. Main sessions held over 3 weeks.
Study NCT01492530 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard HIV Education & Risk Reduction
Description: Single, individual counseling and education session. Lasting 20-30 minutes.
Study NCT02730364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C
Description: One sachet is provided for each participant randomized to the Theraflu Night powder containing paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C as oral solution.
Study NCT04144504 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Retrievable metallic stenting
Description: Use of retrievable metallic stents for the treatment of biliary anastomotic stricture after liver transplantation
Study NCT04144504 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plastic stenting
Description: Use of plastic stents
Study NCT04427501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3819253
Description: Administered IV
Study NCT04427501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3832479
Description: Administered IV
Study NCT03123731 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Arm
Description: Wearing Physical Activity Monitor
Study NCT03123731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iSTEP
Description: Physical Activity Intervention
Study NCT03123731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iSTEP
Description: Physical Activity and Diet Intervention
Study NCT06602947 — intervention group
Intervention type: OTHER
Intervention: Low flow anaesthesia using ASA enviormental sustanibility commitee recomendation
Description: 1. Induction: Set the Vaporizer to Deliver a Concentration Greater than Intended~2. Intubation: Turn Off the Fresh Gas Flow, Not the Vaporizer.~3. Maintanance: Minimize Fresh Gas Flow During Maintenance.
Study NCT04427501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3853113
Description: Administered IV
Study NCT04427501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study NCT02638935 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound- Virtual Touch Tissue Imaging Quantification
Description: Siemens Medical Solutions USA, Inc. (Mountain View, CA) has implemented Virtual Touch Tissue Imaging Quantification (VTIQ) technology on a commercially available general purpose US imaging system (trade name: Acuson S2000 or S3000). This system has received clearance under Food and Drug Administration (FDA) 510(k) number K072786 (S3000) and K130881 (VTIQ). The technology uses a set of tailored US pulses (Acoustic Radiation Force Impulse, ARFI) to induce shear waves in breast tissue due to tissue displacement. A set of standard B-mode pulses detect the perpendicular shear waves. The displacement signals can be processed using algorithms on a Virtual Touch IQ-equipped system in order to calculate the shear wave velocity.
Study NCT04083612 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Venapuncture
Description: Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of ixekizumab
Study NCT04083612 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Patient questionnaires
Description: The study participant will complete the Dermatology Quality of Life Index (DLQI) and EQ5D5L questionnaires at each study visit.
Study NCT02751567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BAY987516
Description: 50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.
Study NCT02751567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Untreated skin
Description: One site is patched without treatment as control
Study NCT03371030 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pronatus quadratus reparation
Description: Displaced and intra-articular distal radius fractures treated with volar approach and plate fixation. Pronator Quadratus muscle repair.
Study NCT03371030 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pronatus quadratus reparation
Description: Displaced and intra-articular distal radius fractures treated with volar approach and plate fixation. Pronator Quadratus muscle repair.
Study NCT01258335 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3
Description: Omega-3-fatty acids 4 gm oral daily (Total:840mg EPA/2520mg DHA) (1:3 ratio of EPA to DHA) ( 6 capsules fatty acids)
Study NCT01258335 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Olive Oil
Description: ii. Placebo oral daily (6 softgel capsules, each contains 1100 mg olive oil)
Study NCT04144634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening exercises
Description: The intervention group will receive 2 supervised exercise sessions a day. The exercise consists of progressive resistance training based around the movement of standing up/sitting down.
Study NCT04144634 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Stretching exercises
Description: The intervention group will receive 2 supervised exercise sessions a day. The exercise consists of gentle stretching of upper limbs and lower limbs.
Study NCT01394653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM060
Description: oral, with water
Study NCT03207555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: 420 mg by mouth once daily.
Study NCT04888325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral glucose
Description: Oral glucose consumption (1.25 grams/kg in 200 ml water at time 0 and the same amount again at 3 hours). During the 6-hour observation period infusion of normal saline (NaCL 0,9%) at a rate of 0.83 plus Heparin, 800 IU/h with a priming dose of 1000 IU.
Study NCT04888325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous glucose
Description: 10% intravenous glucose infusion at a rate of 3.6 ml/kg/h plus Heparin 800 IU/h with a priming dose of 1000 IU will be administrated for 6 hours. Consumption of 300 ml of water at 0 and 3 hours
Study NCT02457312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: letrozole 10 mg daily for 7 days before suction evacuation
Study NCT02457312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets which look identical to the letrozole tablets for 7 days before suction evacuation
Study NCT01395316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: 10 mg/ml alemtuzumab intravenous infusion, sterile clear, colorless solution. dosage: 2 cycles. Month 0 dosed over 5 consecutive days: month 12 dosed over 3 consecutive days.
Study NCT01461239 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fiber post and resin core - self-adhesive cement
Description: pre-fabricated glass fiber posts, cemented with self-adhesive resinous cement
Study NCT01461239 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cast post and core
Description: Ni-Cr alloy cast post and core luted with self-adhesive resin cement
Study NCT01461239 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fiber post luted with conventional resin cement
Description: fiber post luted with conventional etch-and-rinse adhesive system and conventional resin cement, followed by core construction with composite resin
Study NCT02762812 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-055
Study NCT02762812 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Remicade®
Study NCT01004380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Farletuzumab, Carboplatin, and PLD
Description: All subjects will receive approximately 6 cycles with carboplatin (AUC5-6) i.v. and PLD (30 mg/m2) i.v. on Day 1 of every 4-week Combination treatment cycle. In addition, subjects will also receive weekly farletuzumab at 2.5 mg/kg administered i.v. Following completion of the Combination treatment period (carboplatin/PLD/farletuzumab therapy),maintenance treatment with single agent farletuzumab will be administered once Q3W at 7.5 mg/kg until disease progression as defined by GCIG CA-125 (i.e., CA-125 is less than or equal to 2 × (ULN) documented on 2 occasions) or modified RECIST v.1.0 using CT or MRI.
Study NCT01885325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity Preschool Intervention
Description: Preschools randomized to the multi-component physical activity preschool intervention received four major components:Move IN (physical education and other indoor activity programming), Move OUT (recess and structured outdoor activity), Move to Learn (Physical activity in classroom, academic lessons), and enhancing the social environment to promote PA.The focus in the physical education classes, recess, daily lessons, and reduction of sedentary time will be on providing activities that 3-to 5-year-old children enjoy.
Study NCT01391585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message prompts
Description: In this single armed intervention, patients will receive text message prompts
Study NCT04225221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: During estradiol administration, 2mg of estradiol is given twice daily via oral capsule.
Study NCT04225221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronized progesterone
Description: During progesterone administration, 200mg of progesterone is given twice daily via oral capsule.
Study NCT04225221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Initial 3.75 mg intramuscular injection administered approximately Day 6 of menstrual cycle and then monthly thereafter for a total of 3 months.
Study NCT04225221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Capsule
Description: Placebo is administered during the addback phase when participants are not taking active medication. Placebo is given so that medication administration occurs throughout the entire 8-week addback period in order to blind participants to when and for how long they are on the active medication.
Study NCT01988623 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pivotal Response Treatment (PRT)
Study NCT01395979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy for Sexual Risk
Description: Eight weekly sessions, 4 modules.
Study NCT01395979 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Psychotherapy
Description: Eight weekly sessions
Study NCT01395979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual Risk Reduction Intervention
Description: Two weekly sessions.
Study NCT01395979 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sexual Risk Reduction Intervention
Description: Two weekly sessions.
Study NCT02710903 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stent-induced biofilm overgrowth
Description: Customized stents will be fabricated for each subject. Stents will be fabricated to resemble an acrylic mouth-guard but extended to cover approximately 2mm over gingival margins. Stents will form a seal and rest on the gingiva, but will be relieved on the tooth and tissue side except for the occlusal surfaces to avoid disturbing plaque or gingival tissues. Acrylic stents will abstained from brushing and flossing teeth in one maxillary and one mandibular posterior sextant during a three- week period. Patients will be monitored for safety every week and after the induction of experimental biofilm overgrowth through 21 days
Study NCT02694939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAND (Behavior Therapy + Motivational Interviewing)
Description: Parent-teen collaborative skills based behavior therapy targeting Executive functioning and Delay Aversion in Teens
Study NCT02694939 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Community Therapists free to deliver any therapy they feel is indicated.
Study NCT03774966 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block + Catheter & IPACK block
Description: Adductor Canal Block + Catheter \& IPACK block
Study NCT03774966 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal block + catheter
Description: Adductor canal block + catheter
Study NCT01096134 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV Vaccine (Gardasil)
Description: HPV Vaccine Administration: According to the CDC, Gardasil should be delivered through a series of three intra-muscular injections over a six-month period. The second and third doses should be given two and six months after the first dose. The vaccine can be administered at the same visit as other age-appropriate vaccines, such as Tdap, Td, MCV4, influenza, and hepatitis B vaccines. Providers should consider a 15-minute waiting period for vaccine recipients following vaccination.~FDA's Approval of Gardasil (June 8, 2006) lists the following information on product Formulation: Each 0.5 mL dose of the vaccine contains:~20 mcg of HPV 6 L1 protein 40 mcg of HPV 11 L1 protein 40 mcg of HPV 16 L1 protein 20 mcg of HPV 18 L1 protein 225 mcg aluminum (as amorphous aluminum hydroxyphosphate sulfate adjuvant) 9.56 mg of sodium chloride 0.78 mg of L-histidine 50 mcg of polysorbate 80 35 mcg of sodium borate water for injection
Study NCT01406340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg GSK1278863
Description: 5 mg per day administered orally for 14 days for normal subjects and subjects with Stage 3/4 renal function; 5 mg per day administered orally for 15 days for subjects with Stage 5 renal function
Study NCT01216384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800
Description: In the SRD part subjects will receive a single dose and in the MRD part subjects will receive a total of 14 doses.
Study NCT01216384 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will receive according to the dose group matching number of placebo tablets
Study NCT02564926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Subject who will be randomized to the 'Dapagliflozin arm' will be treated with dapagliflozin 10mg + Metformin 1000 mg as Diabetes Treatment
Study NCT02564926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Subject who will be randomized to the 'Glimepiride arm' will be treated with glimepiride 1-2mg + Metformin 1000 mg as Diabetes Treatment
Study NCT00232141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: 75mg BID (can be titrated up to 150mg BID on day 4 based on individual response and up to 300mg BID at the end of week 1, visit 3 and end of week 2, visit 4)
Study NCT00232141 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04637477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual ELM
Description: Participants will attend 1.5-hour virtual group-based sessions for 12 weeks. The program includes physical activity, cooking demonstrations, and group discussions. All sessions are led by a registered dietitian and health psychologist.
Study NCT00516243 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT00516243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT00516243 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT00516243 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT00516243 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT00516243 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00516243 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00516243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: defined green tea catechin extract
Description: Given PO
Study NCT02881957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Study NCT02881957 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral syrup placebo
Study NCT02858869 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02858869 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS
Study NCT01351753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT01351753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT01351753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat
Study NCT01351753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Study NCT01351753 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills and capsules for metformin, orlistat and topiramate
Study NCT02916680 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreatic islet transplantation in the anterior chamber
Description: Transplantation of allogeneic pancreatic islet cells into the anterior chamber of a severely visual impaired diabetic human eye
Study NCT03330353 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pupillometry
Description: Use of pupillometry to assess melanopsin-light pathway in patients with neurodegenerative diseases
Study NCT00012298 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT00012298 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan
Description: Given IV
Study NCT00012298 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: indium In 111 ibritumomab tiuxetan
Description: Given IV
Study NCT00012298 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oprelvekin
Description: Given subcutaneously
Study NCT00012298 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously
Study NCT01946841 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RealDiet®Renal
Study NCT03341351 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instructional video
Description: Instructional video using the modified beef tongue model
Study NCT03341351 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instructional workshop
Description: Instructional workshop using the modified beef tongue model.
Study NCT01703663 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EPAP
Study NCT00639210 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: supervised training
Description: Design: supervised training is organised for the exercise group once a week in groups of 10 to 15 subjects. The training is guided by an experienced physical therapist.Content: The supervised training of the exercise group consists of two different classes alternating at four week periods; step aerobics class and circuit training class. The 60-minute aerobics and circuit training classes also include warming-up and cooling-down periods both lasting 10-15 minutes.
Study NCT00846547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbaclofen
Description: variable dose from 1mg bid to 10 mg tid, oral capsule, 8 week treatment period
Study NCT00409773 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ezetimibe (+) simvastatin
Description: Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg or 10/40 mg.
Study NCT00409773 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Comparator: atorvastatin calcium
Description: Atorvastatin will be supplied in 10mg, 20mg and 40mg tablets.~Each patient will receive 1 active treatment dose \& 2 Placebo doses at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 6 weeks.
Study NCT04396756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLN-74809
Description: PLN-74809